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In the Second Annual National Cancer Institute’s Workshop on the Biology, Prevention, and Treatment of
Relapse after Hematopoietic Stem Cell Transplantation, the Scientiﬁc/Educational Session on the Prevention
and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic
approaches since the ﬁrst relapse workshop. Recent insights that might provide a basis for the development of
novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor
lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed pre-emptive
and maintenance strategies to prevent relapse after transplantation, for example, recent promising results
suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an
overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI,
combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter
addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and
immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and
modulation of costimulatory pathways.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Cancer relapse remains the major cause of treatment
failure after allogeneic hematopoietic stem cell transplan-
tation (AlloSCT). In 2009, the ﬁrst National Cancer Institutee
sponsored workshop on the biology, prevention, and
treatment of relapse published extensive reviews of disease-
speciﬁc prevention and treatment strategies [1,2]. Progress in
prevention and treatment was emphasized in the second
workshop as well and focused on ideas that might provide
a basis for the development of novel, practical clinical trials.
Use of new agents, optimal utilization of donor lymphocyte
infusion (DLI) and immunomodulatory therapeutics, and
investigation of targeted interventions (eg, geneticallyedgments on page 11.
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13.08.012modiﬁed donor cells) and of novel cellular therapies are
areas of ongoing study in the ﬁeld. Promising advances re-
ported since the ﬁrst workshop are discussed here.
I. PREVENTION
Prevention is likely the most feasible and effective means
of managing relapse after AlloSCT. In the case of acute
leukemias, because even extraordinarily low-level minimal
residual disease (MRD) is associated with a high risk of
relapse, the goal of prevention should be to achieve an MRD-
negative state [3]. While most clearly deﬁned for leukemias,
the goal of MRD-negative remission is also relevant to
relapse prevention for indolent malignancies and after
reduced-intensity AlloSCT, that is, in settings where remis-
sion is established some time after AlloSCT. Our ability to
target prevention interventions at individuals whose cancers
have the highest risk of relapse is improvingly rapidly, with
emerging data from molecular, proteomic, and genomic
tumor investigations leading to better-informed relapse riskSociety for Blood and Marrow Transplantation.
Table 1
Strategies for Relapse Prevention
Improved preparative therapy
 Incorporating new drugs with stronger antileukemia activity and/or
less toxicity without compromising dose intensity
 Examples under investigation: monoclonal antibodies (radiolabeled
or not), clofarabine, and treosulfan
Graft engineering
 Allograft enrichment with leukemia- or lineage-speciﬁc cytotoxic
T lymphocytes
 Graft depletion of alloreactive T cells
 NK cell enrichment or adoptive transfer
Pre-emptive treatment
 Monitoring for MRD (cytogenetics, PCR, ﬂow cytometry, etc.)
 Intervention based on detection of MRD
 Therapeutic approaches: pharmacologic, immunologic, and cellular
therapies
Early withdrawal of immunosuppression
 High risk of GVHD may offset reduced relapse risk
Maintenance
 Relapse risk deﬁned by pretransplantation parameters (eg, advanced
disease stage, presence of high-risk karyotype or genetic mutation, or
detection of MRD before and/or after AlloSCT)
 Therapeutic approaches: pharmacologic, immunomodulatory, and
cellular therapy
 Approaches under investigation (AML): azacitidine, FLT3 inhibitors
Ideal maintenance agent
 Documented activity against the disease
 Acceptable nonhematologic toxicity (will be tolerated early after
transplant)
 Acceptable myelotoxicity (will not interfere with engraftment)
 Minimal drug interactions
 Will not inhibit GVT
 Will not worsen GVHD
Caveats to maintenance strategies
 Dose is likely to be lower than in other scenarios
 Dose escalation trials are essential and randomized trials ultimately
necessary given multiples confounding variables
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detecting residual disease [5-7]. Precise application of pre-
emptive strategies that permit interventionwhen the burden
of disease is minimal could improve our ability to eradicate
malignancy before overt relapse. Indeed, many investiga-
tional treatmentsdeven with modest efﬁcacy in established
relapsedmight signiﬁcantly improve AlloSCT outcomes if
applied in the preventive setting. Preventive therapy deci-
sions pose a dilemma: Withholding potentially efﬁcacious
therapy until relapse is detected compromises the patient’s
chance of cure, yet administering potentially toxic therapy
without evidence of relapse results in overtreatment for
some. Toxicity is a major concern in preventive therapy,
particularly in the early months after AlloSCT, when side
effects (eg, myelosuppression, rash, diarrhea) and drug
interactions present signiﬁcant management challenges,
yet also when relapse often occurs and interventionmight be
most effective [8].
Strategic aims of prevention include (1) improving
disease control before AlloSCT, (2) increasing graft-versus-
tumor (GVT) potency of the transplant, (3) maintaining
disease control while the allograft matures, and (4) detecting
and pre-empting an impending relapse (Table 1). Preventing
relapse in individuals whose cancers are active or demon-
strate high-risk biology may require the use of multiple
strategies.
Pretransplantation approaches may permit use of agents
with signiﬁcant hematologic toxicity but require pharma-
cokinetic consideration of potential effects on donor stem
cell and lymphocyte populations. Use of novel agents (tar-
geting signaling pathways, growth factors, cell surface anti-
gens, etc.) may deepen remissions through effects on cancer
cells or the tumor microenvironment and thus improve
outcomes. A role for novel agents in the pretransplantation
setting is suggested by observations of improved AlloSCT
outcomes after their use in “bridge” therapy, such as with
tyrosine kinase inhibitors in Philadelphia chromosomee
positive acute lymphoblastic leukemia (ALL) [9] and bren-
tuximab vedotin in Hodgkin’s lymphoma [10]; distinct
toxicity proﬁles and uniquemechanisms of action have led to
investigation of incorporating monoclonal antibodies into
reduced-intensity conditioning regimens, resulting in
immunomodulatory as well as direct antitumor effects [11].
New cancer drugs with novel targets and innovative
methods of drug delivery are entering the clinic at
a phenomenal rate; their potential to permit or augment GVT
is an important research opportunity.
Transplant modiﬁcations to potentiate GVT effects may
incorporate donor selection tactics, immunotherapeutic
maneuvers, and tumor-speciﬁc immunotherapies. Recent
advances in our understanding of natural killer (NK) immu-
nogenetic inﬂuences on transplantation outcome, including
relapse risk (particularly in acute myelogenous leukemia
[AML]) may yield opportunities to prevent relapse through
donor selection based on KIR genotyping in the context of
HLA mismatch [12]. Early withdrawal of immune suppres-
sion, with or without prophylactic DLI, is another consider-
ation in patients at very high risk of relapse, but randomized
trial data are lacking and there is signiﬁcant risk of graft-
versus-host disease (GVHD) [13]. Furthermore, when used
to pre-empt impending or early leukemia relapse, these
immunotherapeutic maneuvers appear to have limited
activity outside of chronic myelogenous leukemia and result
in considerable GVHD morbidity [14]. The morbidity of
prophylactic DLI may be reduced in the setting ofT celledepleted allografts or mixed chimerism [15,16].
Interestingly, preliminary results of administering ex vivo
activated DLI prophylaxis suggest fairly modest GVHD
toxicity after reduced-intensity conditioning AlloSCT with
alemtuzumab [17]. Efforts to optimize selective subset
depletion of DLI (or allograft) continue, attempting to reduce
risk of GVHDwhile maintaining protection from relapse [18].
There has been signiﬁcant progress in developing tumor-
targeted immunotherapies, including tumor vaccines,
genetically modiﬁed T cells (discussed below in III. Strategies
to Enhance T Cell Function), and selectively expanded
antigen-speciﬁc T cells [19]. The early post-transplantation
period may be an ideal time for their administration, when
minimal tumor burden coincides with lymphopenia-induced
homeostatic cytokine abundance and increased efﬁciency of
antigen-speciﬁc lymphocyte proliferation[20]. The use of
novel (eg, targeted) agents in maintenance therapy requires
phase I evaluation of cumulative and overlapping toxicities
(eg, with conditioning and immunoprophylaxis agents), with
particular attention to effects on rapidly expanding progen-
itor and lymphocyte populations.
Maintenance therapeutics may be effective in relapse
prevention, providing early tumor control and, potentially,
immunomodulatory support for the development of an allo-
geneic immune response. Acute leukemia relapse poses
a particularly great management challenge after AlloSCT due
to rapid cell growth and disease progression once recurrence
is detected; as such, maintenance approaches for acute
leukemia may be informative in indolent malignancies as
well. A phase I trial at M.D. Anderson deﬁned a safe, low-dose
azacitidinemaintenance regimen (32mg/m2/day, days 1-5 of
Figure 1. Donorecell consolidation of remission for AML relapse after AlloSCT.
Analysis of European Bone Marrow Transplantation Registry data from 38
patients in CR after ﬁrst-line cytoreductive therapy for relapsed AML after
AlloSCT demonstrated improved OS with use of donor cells for consolidation:
55%  11% vs. 20%  10% (P ¼ .038). DLI and second AlloSCT were considered as
time-dependent variables. Adapted from [30].
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suggesting improved event-free and overall survival (OS) and
less chronic GVHD [21]; an ongoing trial is examining 1 year
of maintenance with this regimen (NCT00887068). Others
have conﬁrmed the favorable toxicity proﬁle of low-dose
azacitidine maintenance, with indirect evidence suggesting
azacitidine maymediate enhanced GVT effects and modulate
GVHD by increasing T cell tumor antigen responsiveness and
numbers of circulating regulatory T cells [22,23].
Pre-emptive treatment strategies are being investigated
that, by using monitoring, initiate therapy upon detection of
MRD or other biologic surrogate of impending relapse. In the
RELAZA trial [24], azacitidine was used to treat patients with
imminent relapse as deﬁned by decreasing CD34þ cell donor
chimerism (“CD34 chimerism”) after AlloSCT. Twenty
patients with decreasing CD34 chimerismwhile in complete
hematologic remission received 4 cycles of standard-dose
azacitidine (75mg/m2/day for 7 days). Responses were
observed in 16 patients during treatment, with CD34
chimerism either increasing (50%) or stabilizing (30%)
without signs of hematologic relapse. Additional cycles were
given to 11 patients. Although 13 of 20 patients ultimately
relapsed, the time to relapsewas longer than expected in this
very-high-risk cohort, suggesting that a pre-emptive strategy
maybe effective, although alternativemonitoring approaches
and/or use of more intensive pre-emptive therapy may be
necessary.
II. STRATEGIES TO IMPROVE CELL THERAPY FOR
RELAPSE
Donor cell therapy remains the foundation of most
approaches to induce remission for AlloSCT relapse,
attempting to restore or kindle a potentially curative GVT
effect. However, except for chronic myelogenous leukemia
and, to some extent, other indolent malignancies, responses
to unmodiﬁed DLI or second transplantation in overt relapse
after AlloSCT are disappointing. Although data are limited,
adjunctive therapies are now routinely used in conjunction
with donor cells for their direct cytotoxic and/or immuno-
modulatory effects.
Remission Induction before Cellular Therapy
In acute leukemias and other aggressive malignancies,
rapid tumor growth kinetics, a high tumor burden at the time
of relapse detection, and use of immune escape mechanisms
limit the clinical efﬁcacy of DLI alone. Consistent with this,
DLI [25] and second transplantation [26] result in better
outcomes if complete remission (CR) can be induced before
cell therapy, affording time to establish a robust GVT effect
[27] and, perhaps, increase tumor cell immunogenicity as
well [28].
There are no standard cytotoxic regimens for any cancer
relapse after AlloSCT, and an individualized approach to
agents, doses, and schedules is often driven by such factors as
prior chemosensitivity, interval from AlloSCT to relapse, age,
and comorbidities, including GVHD. In AML, approximately
45% of patients achieve CR following standard anthracycline/
cytarabineebased combinations [29,30]. Importantly,
remission induction alone is not sufﬁcient for long-term
disease control in most patients. In a recent European
Group for Blood and Marrow Transplantation analysis of
patients with AML relapse after reduced-intensity condi-
tioning AlloSCT, durable remissions were observed almost
exclusively in patients whose chemotherapy-induced CRwas
consolidated with either DLI or a second SCT [30] (Figure 1).In addition to cytoreduction, chemotherapy given before
donor cell infusion might have immunomodulatory effects
that promote GVT activity, for example, by lymphodepletion,
suppression of regulatory T cells, and/or release of activating
cytokines [31].
Use of Novel Agents
Therapeutic agents with novel mechanisms of action are
under investigation for their ability to control cancer cell
proliferation, including progression after AlloSCT (Table 2).
As compared with conventional chemotherapy, these drugs
often have less systemic toxicity andmight therefore be used
in patients with a recent history of intensive treatment,
including conditioning for SCT, with active GVHD or other
comorbidities. In addition to direct cytotoxic activity, some
drugs (eg, hypomethylating agents, thalidomide and its
derivatives, etc.) reportedly increase antitumor immune
responsiveness by increased tumor immunogenicity [32] and
enhanced activation of T cells and NK cells [33]. These and
other immunomodulatory agents (eg, bortezomib [34] and
rituximab [35]) may have prophylactic or therapeutic beneﬁt
in GVHD and hence may be useful adjuncts to reduce the risk
of GVHD with DLI.
Although the literature on the use of novel agents for
relapse after AlloSCT is predominantly retrospective and/or
anecdotal, monotherapy for overt relapse generally appears
to yield modest responses of limited duration (Table 2).
Further, immunomodulatory effects of even highly targeted
agents can be heterogeneous, yielding unanticipated nega-
tive effects on the immune response (ie, exacerbation of
GVHD and/or interference with GVT). As an example of
interference with GVT, the multietyrosine kinase inhibitor
dasatinib has been shown to potently inhibit effector T cell
function in vivo [36] and could theoretically blunt any GVT
response. Such unexpected “targets” of novel agents high-
light the need for their evaluation in clinical trials, including
assessment of their immunomodulatory properties in the
allogeneic setting.
Cytokines to Augment the Efﬁcacy of Donor Immune Cells
Various cytokines have been investigated for their capacity
to improve the efﬁcacy of donor cells. An older approach
Table 2
New Drugs in Treatment of Relapse after Allogeneic Stem Cell Transplantation
References Study Design Diagnosis Number
Treated
Dosage Responses DLI Outcome Remarks
Hypomethylating Agents
Azacytidine
Jabbour, Cancer 2009 Retrospective,
single-center
AML 4/9/4 (17 total) 1,62,440 mg/m2 d1-5,
median 8 courses
ORR: 56%
(33% CR, 22% PR)
No Not reported Patients with
“indolent” disease
reccurrence
Lübbert, BMT 2010 Prospective pilot AML/CMML 26 100 mg within 3 d CR: 16%, temporary
disease control: 50%
Day 10 of each course
in 73% of patients
2-yr OS 16%
Czibere, BMT 2010 Retrospective,
multicenter
AML/MDS 22 100 mg/m2 d1-5, q 4w,
up to 8 courses
ORR 72% (23% CR) In 82% of patients Median OS:
144 d, 2-yr OS: 23%
Bolanos-Meade,
BBMT 2011
Retrospective,
single-center
Myeloid malignancies 10 Various CR: 60%, SD: 10% No Median OS: 422.5 d Patients without
circulating blasts
only
Schröder, ASH (#656)
2011; ASH (#1964)
2012
Propspective,
single-arm,
multicenter,
phase 2
AML/MDS 30 100 mg/m2 d1-5, q4w,
up to 8 courses
ORR: 47% (CR: 23%, PR:
7%, SD: 17%)
Increasing doses after
alternating courses
Median OS: 117 d Up-regulation of
regulatory T cells
following 5-azacytidine
Tyrosine Kinase Inhibitors
(Exclusive of CML)
Imatinib
Wassmann, Blood
2005
Prospective,
single-arm,
multicenter
Phþ ALL 27 400 mg/d-800 mg/d Molecular CR: 54% No 2-yr DFS:
early responders 54%;
nonresponders 8%
Nilotinib
Tiribelli, Leuk Res
2009
Case report Imatinib-resistant
Phþ ALL
1 400 mg b.i.d Molecular CR Monthly DLI CCR
Dasatinib
Ishida, Int J Hematol
2010
Case report Phþ ALL 1 Not reported Molecular CR No CCR following SCT2 Particular side
effects after SCT2
Czyz, Med Oncol. 2010 Case report Phþ ALL, persistent
MRD
1 Not reported Molecular CR No CCR
Conchon, BMT 2010 Case report Imatinib-resistant
Phþ ALL
1 140 mg/d, initially
combined with VCR and
dexamethasone
Molecular CR No CMR after 8 mo of
dasatinib maintenance
Tchibana, Leuk
Lymphoma 2011
Case report Imatinib-resistant
Phþ ALL
1 140 mg/d (salvage),
80 mg/d (maintenance)
Minor hematological
response as salvage,
molecular CR as
maintenance
after SCT2
No CMR after SCT2 and
short dasatinib
maintenance
Sorafenib
Metzeler, Blood 2009 Compassionate-use
results
FLT3-ITD þ AML 5 2  400 mg/d CCR in 3/5 patients No 2  durable remission
Sharma BBMT 2011 Retrospective,
single-center
AML 16 2  400 mg/d -600 mg/d þ/
chemotherapy
No CR, reduction of
circulating blasts in 80%
No; 3 pts. received SCT2 Median OS 83 d Sorafenib regarded
as not effective in
early relapse
Immunomodulators
Thalidomide
Kröger, Blood 2004 Prospective,
single-center,
phase 1/2
Multiple myeloma 18 100 mg/d, escalation to
300 mg in case of no
response
ORR: 67%, CR: 22 Escalating dosages,
Day 14 of every cycle
2-yr OS: 100%, DFS: 84% Only patients
refractory to or
relapsing after
prior DLI
(Continued)
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Table 2
(Continued )
References Study Design Diagnosis Number
Treated
Dosage Responses DLI Outcome Remarks
Lenalidomide
Minemma, Leukemia
2011
Retrospective,
single-center
Multiple myeloma 16 25 mg/d, þ dexamethasone
with progression
ORR lenalidomide only:
46%, þ Dex: 87.5%
No (some with prior
DLI)
Not reported Severe aGvHD after
lenalidomide alone
Lioznov, BMT 2010 Retrospective,
single-center
Multiple myeloma 24 15 mg/d-25 mg/d, þ/
dexamethasone
ORR: 66%, (CR: 8%, VGPR:
8%, PR: 50%, SD: 13%)
No Median OS: 19.9 mo,
median TTP: 9.7 mo
Less GvHD, increase
of activated NK and
T cells
Spina, Leuk Lymphoma
2011
Retrospective,
multicenter
Multiple myeloma 13 10 mg/d-25 mg/d þ
dexamethasone
ORR: 100%, 69% long-term
responders
No Not reported Increases the
frequency of
CD4 þ Foxp3 þ T cells
Bortezomib
Kröger, Exp Hematol
2006
Prospective pilot Multiple myeloma 11 1.3 mg/m m2 days 1,4,8
and 11
CR: 30%, PR: 50%, MR: 20% No Not reported Patients with
measurable disease
only, progressive
disease excluded
El-Ceikh,
Hematologica 2008
Retrospective,
multicenter
Multiple myeloma 37 1.0 mg/m2-1,3 mg/m2 days
1,4,8,11 þ/
dexamethasone
ORR: 73% (CR: 19%, VGPR:
19%, PR: 36%)
No 18 mo OS 65%
Monoclonal Antibodies
Rituximab
Wudhikarn, BBMT
2011
Retrospective NHL 27 Not reported; additional
chemotherapy in 7 pts.
ORR 44% Not reported Median response
duration: 23 mo (1-68)
Response even in
patients pretreated
with rituximab
Bi 20 (FBTA05)
Buhmann, BMT 2009 Compassionate-use
results
CLL/NHL 6 Escalating doses
(10 mg-2000 mg)
CLL: 3  transient
response, NHL: 1 SD
DLI in escalating doses
or SCT2
Blinatumumab
Handgretinger,
Leukemia 2011
Retrospective,
single-center
Pediatric ALL 3 (2 MRD) 3  CR 2 of 3 relapsed quickly
after stopping drug;
1 CCR after haplo SCT2
Expansion of
donor-derived
T cells in all cases
Brentuximab Vedotin
Gopal, Blood 2012 Prospective,
pooled data
(3 studies)
Hodgkin’s
lymphoma
25 1.2 mg/kg-1.8 mg/kg, 1-16
(median: 8) cycles
ORR: 50%, CR: 38% No Median PFS; 7,8 mo,
median OS: not reached
CMML indicates chronic myelomonosytic leukemia; MDS, mydelodysplastic syndrome; ORR, overall response rate; CCR, complete cytogenetic response; CMR, complete molecular response.
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phage colony-stimulating factor and/or IFN-a and DLI. Both
cytokines have been shown to increase the capacity of
dendritic cells and leukemia cells to present target antigens
and to provide costimulatory signals and adhesion molecules
for improved donor T cell stimulation. In murine models,
CD8-dependent GVHD and GVT effects are enhanced by IFN
signaling through its ability to both sensitize the leukemia
cells to killing and to augment donor cytotoxic T lymphocyte
(CTL) function [37]. Several reports have successfully used DLI
plus IFN-a in diseases with historically poor responses to DLI
alone; however, small, heterogeneous cohorts make it difﬁ-
cult to determine the real contribution of IFN-a [38,39].
Tang et al. [40] reported on 16 patients with relapsed
acute leukemia (AML, 7; ALL, 9) treated with IFN-a plus
granulocyte colony-stimulating factor mobilized donor
leukocytes. IFN-a (3 MU/day) was given from day 5 before
DLI until CR, toxicity, or relapse (median 17 days, range 5 to
50). Twelve of 16 patients achieved CR, including 6 of 9
patients who received no additional cytotoxic therapy. At last
follow-up, seven patients were alive in CR. Comparedwith 14
similar patients treated with DLI alone, IFN-a/DLI resulted in
a higher CR rate (75% versus 14%, P ¼ .001) and improved
leukemia-free survival (50% versus 7%, P ¼ .05), albeit with
increased acute GVHD (56% versus 27%, P ¼ .05).
Another approach to increase the potency of DLI is to
interrupt the counter-regulatory effect of CTLA-4 on T cell
activation through administration of ipilimumab, a neutral-
izingmonoclonal antibody against CTLA-4. In a phase I trial for
post-AlloSCT relapse, some immune-mediated adverse events
were observed, although there was no signiﬁcant GVHD, even
in patients subsequently receiving DLI for disease progression
[41]. Ipilimumab showed modest activity in lymphoid
malignancies, particularly Hodgkin’s lymphoma, with 2 pro-
longed CRs in patients treated at the highest dose level.
Consistent with expected biologic effects, a dose-dependent,
T cell activation and expansion was observed in vivo.
Further, immune-mediated systemic (“abscopal”) anti-
tumor effects of targeted radiation, mediated through novel
tumor antigen expression and inﬂammation-induced re-
cruitment of antigen-presenting cells, are well described,
and synergy with cellular immunotherapy, including CTLA-4
blockade, has been demonstrated in murine models [42]. In
an ongoing clinical phase I/II trial, the National Cancer
Institute is studying radiation-targeted DLI for relapse after
AlloSCT, looking at systemic effects of single-fraction radia-
tion to isolated tumors, including safety, clinical responses
outside the radiation ﬁeld, and effects on allogeneic
lymphocyte populations (NCT00984165).
Second Allogeneic Transplantation
Although there are no prospective trials, second AlloSCT
is frequently used for relapse after AlloSCT, particularly in
acute leukemia. Available evidence is based on retrospective
registry data, mainly with second AlloSCT from the same
HLA-identical related donor. With the important caveat that
the recipients of second AlloSCT represented a highly
selected minority of individuals with relapse [43], reported
long-term OS was between 20% and 30%, with a respective
cumulative incidence of relapse and nonrelapse mortality
(NRM) of around 40% each. Duration of remission after initial
AlloSCT, disease status at initial and second AlloSCT, and age
were the most important factors for OS.
Second AlloSCT after unrelated-donor transplantation,
donor selection for second AlloSCT, and optimal second-transplantation conditioning regimens remain open ques-
tions. National registry studies in Italy and Germany have
examined these issues in relapsed acute leukemia [44,45].
Independent of donor selection at ﬁrst AlloSCT, both groups
found a trend for increased NRM after unrelated-donor
second AlloSCT as compared with second transplantation
with a related donor. However, long-term survivors were
identiﬁed even after 2 unrelated SCTs. The intensity of
second-transplantation conditioning did not appear to
inﬂuence OS, although NRM was lower after reduced-
intensity conditioning.
Use of a different donor for second AlloSCT was generally
not associated with better OS, either in the related or unre-
lated setting. However, after relapse after unrelated-donor
AlloSCT, the German study found a trend for improved OS
after changing to a different unrelated donor in patients
without a history of acute or chronic GVHD after ﬁrst AlloSCT.
This suggests distinct subgroups of patients for whom
increased GVT effects with a different donor may offset the
risk of NRM. Prospective studies are needed to determine
optimal patient selection, donor selection, and conditioning
regimens for second AlloSCT treatment of relapse.
III. STRATEGIES TO ENHANCE T CELL FUNCTION
Novel Cellular Therapies
Improving antitumor potency and speciﬁcity of donor
cellular therapy for relapse after AlloSCTwould optimize GVT
and GVHD reactivity and likely improve efﬁcacy. Minor
histocompatibility antigens are important targets for T
cellemediated GVHD and GVT reactivity [46]. It may be
possible to isolate and expand T cells that recognize minor
histocompatibility antigen selectively expressed on hema-
topoietic cells to induce GVT without GVHD [47]. Alterna-
tively, tumor-associated, overexpressed self-antigens such as
WT-1, proteinase-3, or PRAME are promising targets for T
celledirected GVT responses.
Although feasible, the generation of tumor-speciﬁc CTL
has proven time-consuming and often difﬁcult. An alterna-
tive strategy to enhance GVTactivity is donor Tcell activation
and expansion with CD3/CD28 costimulation ex vivo. In
preliminary studies, ex vivo activated DLI yielded several
responses, notably even in patients with typically DLI-
refractory tumors, such as AML, ALL, and non-Hodgkin
lymphomas, suggesting that activated DLI may offer greater
GVT potency [48]. This also provides a possible strategy to
obtain cells for adoptive immunotherapy for relapse
prevention or treatment after umbilical cord blood trans-
plant when it is not possible to recontact the donor. Based on
a hypothesis that tumor-inﬁltrating lymphocytes found after
AlloSCT relapse are donor cells and an enriched source of
tumor-speciﬁc lymphocytes, a phase I trial demonstrated
donor origin, feasibility, and safety of administering ex vivo
CD3/CD28 costimulated and expanded tumor-derived donor
lymphocytes. It also provided evidence that tumor-antigen
reactive donor T cells were expanded, plausibly yielding
cell products enriched for tumor-speciﬁc CTLs [49]. Although
responses to tumor-derived DLI were of short duration in the
DLI-refractory patients treated, this approach could provide
DLI therapy for patients without another source of donor
cells.
It is possible to activate and expand donor cells with other
biologic activities. For instance, cytokine-induced killer (CIK)
cells can be generated in vitro and expanded for clinical use.
These unique cells are derived from cytotoxic T cells that
express CD3 and CD56 and recognize targets through the
Figure 2. Theoretical relative therapeutic potential of cellular therapies for relapse. The shaded quadrant represents the zone of optimal speciﬁcity with respect to
tumor versus off-target cytotoxic tissue damage, which maximizes antitumor potency and minimizes cell-mediated morbidity. Conventional DLI and second AlloSCT
(depicted in red) are the currently available cell-based treatments for relapse, against which novel therapies (blue) will be judged. TAA, tumor-associated antigen;
MiAg, minor histocompatibility antigen.
M. de Lima et al. / Biol Blood Marrow Transplant 20 (2014) 4e1310NKG2D activating receptor. Importantly, cell killing is HLA
unrestricted and TCR independent, can kill leukemia cells
in vitro, and can induce minimal GVHD in animal models.
Expanded donor CIK cells were given to a small number
of patients with relapsed malignancy after AlloSCT [50].
Although there was minimal GVHD, only 1 of 18 patients had
a sustained remission; however, a number of prolonged
remissions, several in patients who did not respond to
conventional DLI, suggest that CIK cells may contribute to
GVT activity without GVHD. For maximum effect, CIK cells
will likely have to be used before overt hematologic relapse
in high-risk patients (ie, in a preventive or pre-emptive
approach) or in combination with other relapse therapies.
In addition to the critical role of T cells, NK cells are
increasingly implicated as important mediators of GVT
activity, particularly in myeloid diseases and in the setting
of haploidentical transplant [51]; NK cell biology and impli-
cations for graft selection and ways to exploit their thera-
peutic potential were discussed in detail during the
workshop [20,52]. Plausibly, it might be possible to augment
NK-mediated GVL through increasing availability of endog-
enous IL-15, a key cytokine for NK cell development,
expansion, and function in vivo. This theory can now be
tested in the clinic, with recombinant human IL-15 now in
clinical trials; alternatively, the novel IL-15 super agonist,
ALT-803, which has shown promise in early biologic testing
[53], is slated to begin clinical testing later this year.
Targeted Therapies
Targeted therapies hold the promise of antitumor activity
without inducing nonspeciﬁc GVHD. This is particularly true
for targeted antibodies (reviewed in 2009 Workshop
Proceedings [1]). A key limitation is that tumor-speciﬁctargets are not well deﬁned for most hematologic malig-
nancies. Potential targets have been exploited in previous
studies, for example, with the monoclonal antibodies CD52
(alemtuzumab) and CD20 (rituximab) and with anti-
bodyedrug conjugates, such as CD33 (gemtuzumab ozoga-
micin), CD25 (denileukin diftitox), and CD22 (inotuzumab
ozogamicin), all small studies demonstrating limited clinical
activity in AlloSCT relapse [1]. The limited activity might be
related in part to variable or weak target expression or
variable or incomplete activity of the targeted agent. In
addition, nonspeciﬁc toxicities develop when the target is
broadly expressed on other cell types and tissues.
CD19 is an ideal tumor target, with expression largely
restricted to normal and malignant B cells. The antibody
blinatumomab is a bispeciﬁc T celleengaging antibody
speciﬁc for CD19 and CD3. It serves to direct cytotoxic T cells
to CD19-expressing target cells [54] and has activity in both
non-Hodgkin lymphoma and ALL. Impressively, in ALL
relapse after conventional chemotherapy, blinatumomab
induced CR in 68% of patients [55]. Few patients have been
treated with blinatumomab for ALL relapse after AlloSCT. A
small case series reported hematologic CR in 3 of 3 pediatric
patients, although disease rapidly recurred in 2 of those
treated [56]. Given its speciﬁcity, clinical activity, and toxicity
proﬁle, it is reasonable to test blinatumomab in a larger
group of patients with post-AlloSCT ALL relapse, alone or in
combination with other agents.
Targeted cellular therapy may be even more promising
because T cells can both expand, amplifying their effect, and
persist in vivo, providing long-term vaccine-like antitumor
activity. Efﬁcient gene transfer techniques nowpermit genetic
modiﬁcation of T cells to confer novel antigen speciﬁcity by
stably expressing novel T cell receptors, that is, chimeric
M. de Lima et al. / Biol Blood Marrow Transplant 20 (2014) 4e13 11antigen receptors (CARs), on their surface. CAR-modiﬁed
T cells become activated and kill in an antigen-dependent
but HLA-independent manner, making this an attractive
approach for any tumor with a deﬁned target. It was recently
shown that T cells expressing a CAR targeting CD19 linked to
a potent signaling domain (CD137/4-1BB) demonstrated
massive in vivo expansion, tumor-speciﬁc trafﬁcking, and
long-term persistence in vivo. CD19-CARs have induced rapid
and sustained antitumor activity in chemotherapy-refractory
chronic lymphocytic leukemia [57] and B cell lymphomas
[58]. These cells have also induced remission for refractoryALL
and for relapse of ALL after umbilical cord blood trans-
plantation [59]. It will be of great interest to continue to test
this approach in relapse after AlloSCT, particularly for patients
with ALL, chronic lymphocytic leukemia, and non-Hodgkin
lymphoma; ongoing trials evaluating CD19-CAR transduced
donor T cells appear to be promising [59,60].
Any new cellular therapy ultimately has to be judged in
relationship to conventional DLI or second allogeneic SCT.
For most indications other than chronic myelogenous
leukemia, conventional DLI has some, albeit disappointing,
activity and is associated with signiﬁcant GVHD-related
toxicity. Second AlloSCT may be curative for a subset of
patients with extensive morbidity and mortality. Figure 2
depicts a theoretical assessment of the potential for some
investigational cellular therapies to treat relapse, with the
ideal cell therapy providing maximal antitumor activity with
minimal nonspeciﬁc cell-mediated toxicity. It is hypothe-
sized that nonspeciﬁc ex vivo activation of donor T cells or
generation of minor antigenedirected T cells would enhance
activity of DLI, although limited studies suggest toxicity is
similar to DLI. We believe that engineered tumor anti-
genespeciﬁc and CAR-modiﬁed donor T cells (such as
CD19-directed CARs) have the potential to provide potent
antitumor activity with limited if any GVHD, a hypothesis
supported by early clinical observations [59-61]. Numerous
other cell therapy approaches hold promise but as yet have
shown limited clinical activity. We recognize there are
limited clinical data for any novel cell therapy other than
conventional DLI, and so where any cellular therapymight ﬁt
into this idealized perspective could be subjected to vigorous
debate. It will certainly require constant modiﬁcation as
well, as we believe the next few years will bring develop-
ment of new therapies or modiﬁcations of existing ap-
proaches leading to enhanced activity and limited toxicity to
treat relapse after AlloSCT.
FUTURE DIRECTIONS AND RESEARCH PRIORITIES
The Scientiﬁc Session on Prevention and Treatment of
Relapse highlighted ongoing clinical development of new
management approaches and, importantly, identiﬁed recent
ﬁeld advances that are ripe for clinical development. We
remain optimistic about the future potential to treat relapsed
disease. Although no major breakthroughs have occurred in
treatment results, major advances have been made in
developing potential novel strategies. Several trial concepts
were discussed in the Workshop’s Protocol Planning
Committee meetings. The use of novel agents, immune
stimulation and modulation, and enhanced cellular thera-
pies all constitute critical areas for future study. Studying
novel immune modulators and combinations of immune
modulation with cellular therapy are particularly relevant
and appropriate for initiation of multicenter prospective
trials to treat relapse. A major achievement of the second
workshop was participant commitment to the establishmentof an international transplant relapse consortium and
development of a platform for conducting such multi-
institutional trials to speed clinical investigation of relapse
prevention and treatment strategiesdof both novel
approaches as well as those more commonly used, albeit
understudied.
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